DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.  Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15 billion by 2030.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

Codon

SEPTEMBER 29, 2024

It suggested that, in the future, certain classes of drugs, specifically genetic therapies, could be screened entirely virtually via models of life. 2028 Over the next year, the scientific community ferociously interrogated the model. Of particular interest was how genetic therapies were delivered.

Engineering 142

Engineering Virus DNA Therapies 142

DrugBank

SEPTEMBER 26, 2024

This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles. billion by 2028. One key challenge is the development of biosimilars for complex biologics, such as monoclonal antibodies used in cancer treatment and gene therapies.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. An example: For GSPR 12 on devices that incorporate medicinal products, rather than citing the European pharmaceutical regulations (Directive 2001/83/EC), the U.K. government continued to recognize CE-marked products for a limited time.

Regulations 40

Regulations International Production Government 40

The Pharma Data

NOVEMBER 4, 2020

“We are excited to be nearing the EMA’s regulatory decision on VASCEPA and are busy preparing for our anticipated commercial launch in Europe, where there is a large and growing opportunity for Amarin to bring this proven effective therapy to the millions of patients at high risk for cardiovascular events. About Amarin.

Production 40

Production Trials FDA Disease 40